Company / Return on Assets (ROA)
GT Biopharma, Inc. Return on Assets (ROA) History
FY2011-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
3.8%
FY2017
5-year range
-60603.7% / 3.8%
FY2013-FY2017
Trend
+100.0%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) returned to growth in FY2017 after 2 years of decline, reaching 3.8%.
Based on SEC 10-K filings.
3.8% in FY2017 with a 5-year CAGR of +1641.0%.
Improved from -2645.2% to 3.8% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +60.3pp
- 5-Year Change
- +1641.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2017, return on assets (roa) increased 100.0% year-over-year.
- Lowest return on assets (roa) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2020 | - | - |
| FY2017 | 3.8% | +100.0% |
| FY2016 | -60603.7% | -2191.1% |
| FY2015 | -2645.2% | -4588.3% |
| FY2014 | -56.4% | +98.4% |
| FY2013 | -3517.7% | -114.9% |
| FY2012 | -1637.2% | +29.5% |
| FY2011 | -2321.7% | - |
As of FY2017 · SEC 10-K · Updated Jun 24, 2026